Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization as Conversion Therapy Among Patients With Initially Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice in China

NCT06503250 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06503250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06503250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization as Conversion Therapy Among Patients With Initially Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice in China
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
July 19, 2024
Completion date
November 27, 2024
Enrollment
113 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma